AQbD-enhanced green RP-UPLC-PDA methodology for quantification and forced degradation studies for omeprazole, amoxicillin, and rifabutin
Abstract The ternary combination like omeprazole (OMP), amoxicillin (AMX), and rifabutin (RFB) was approved by the FDA in November 2019 for combating Helicobacter pylori infections and ulcers caused by this infection. This study aims to develop and authenticate a robust and eco-friendly RP-UPLC tech...
Saved in:
| Main Authors: | S. P. Ashnah Baffinsha, Vijayageetha Ragupathi, Hemanth Kumar Chanduluru |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13065-024-01337-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AQbD Approach Applied to NIR in a Complex Topical Formulation: Bifonazole as Case Study
by: Lucas Chiarentin, et al.
Published: (2025-06-01) -
Ascorbigen — Rifabutin Toxicity Modifier
by: E. R. Pereverzeva, et al.
Published: (2020-12-01) -
Spherical amorphous nanoparticles loading with antituberculosis substance rifabutin
by: A. P. Kaplun, et al.
Published: (2010-04-01) -
Experimental study of the pharmacokinetics of rifabutin in liposomal form
by: M. V. Carlin, et al.
Published: (2013-09-01) -
Segmental retinal arteritis in a case of presumed bilateral rifabutin-associated hypopyon uveitis
by: Shefali Sood, et al.
Published: (2024-12-01)